What's new? Log in Free sign up

Skye Bioscience (SKYE)

Company Profile

Company profile

Ticker

SKYE

Exchange

Website

skyebioscience.com

CEO

Mr. Punit S. Dhillon B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Emerald Bioscience, Inc., LOAD GUARD LOGISTICS, INC., LOAD GUARD TRANSPORTATION, INC., Nemus Bioscience, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Skye Bioscience Pty Ltd. • Emerald Health Therapeutics, Inc. • Avalite Sciences, Inc. • Bird Rock Bio Sub, Inc. • Ruiyi Acquisition Corporation ...

SKYE stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Registration of securities for employees

Quarterly report

7 Nov 24

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

Departure of Directors or Certain Officers

Definitive proxy

Preliminary proxy

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Latest ownership filings

View all

KAITLYN ARSENAULT

Paul A. Grayson

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

JANUS HENDERSON GROUP PLC

Altium Capital Management LP

Financial summary

Financial statements Chart SKYE financial data

Quarter (USD)	Sep 24	Mar 24	Sep 23	Jun 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	76.49 mm	76.49 mm	76.49 mm	76.49 mm	76.49 mm	76.49 mm
Cash burn (monthly)	5.31 mm	(no burn)	1.66 mm	3.26 mm	(no burn)	892.26 k
Cash used (since last report)	14.96 mm	n/a	4.67 mm	9.20 mm	n/a	2.51 mm
Cash remaining	61.54 mm	n/a	71.83 mm	67.30 mm	n/a	73.98 mm
Runway (months of cash)	11.6	n/a	43.4	20.6	n/a	82.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

SKYE institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	64	3	+2033.3%
Opened positions	61	1	+6000.0%
Closed positions	0	0
Increased positions	1	0	NEW
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	195.81 bn	31.41 bn	+523.4%
Total shares	667.33 mm	644.84 mm	+3.5%
Total puts	1.10 k	0.00	NEW
Total calls	1.10 k	0.00	NEW
Total put/call ratio	1.0	–	–

Largest owners	Shares	Value	Change
Versant Venture Capital III	632.74 mm	$10.06 mm	0.0%
5AM Venture Management	10.18 mm	$81.54 bn	NEW
5AM Partners VII	10.10 mm	$0.00	0.0%
Versant Venture Management	2.01 mm	$16.08 bn	+0.0%
Altium Capital Management	1.35 mm	$10.81 bn	NEW
Logos Global Management	1.30 mm	$10.43 bn	NEW
Sphera Funds Management	1.30 mm	$10.40 bn	NEW
BLK BlackRock	1.12 mm	$8.96 bn	NEW
JHG Janus Henderson	905.65 k	$7.29 bn	NEW
Vanguard	833.62 k	$6.68 bn	NEW

Largest transactions	Shares	Bought/sold	Change
5AM Venture Management	10.18 mm	+10.18 mm	NEW
Altium Capital Management	1.35 mm	+1.35 mm	NEW
Logos Global Management	1.30 mm	+1.30 mm	NEW
Sphera Funds Management	1.30 mm	+1.30 mm	NEW
BLK BlackRock	1.12 mm	+1.12 mm	NEW
JHG Janus Henderson	905.65 k	+905.65 k	NEW
Vanguard	833.62 k	+833.62 k	NEW
CVI	679.74 k	+679.74 k	NEW
Driehaus Capital Management	650.76 k	+650.76 k	NEW
Point72 Asset Management	560.00 k	+560.00 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SKYE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Nov 24	Paul A. Grayson	Common Stock	Sell	Dispose S	No	No	4.99	86,244	430.36 k	259,701
18 Nov 24	Punit Dhillon	Common Stock	Sell	Dispose S	No	No	4.99	82,546	411.90 k	329,823
18 Nov 24	Kaitlyn Melanie Arsenault	Common Stock	Sell	Dispose S	No	No	4.99	43,206	215.60 k	166,342
18 Nov 24	Tuan Tu Diep	Common Stock	Sell	Dispose S	No	No	4.99	19,489	97.25 k	82,259
15 Nov 24	Paul A. Grayson	Common Stock	Sell	Dispose S	No	No	5.55	307	1.70 k	345,945
15 Nov 24	Punit Dhillon	Common Stock	Sell	Dispose S	No	No	5.55	364	2.02 k	412,369
15 Nov 24	Kaitlyn Melanie Arsenault	Common Stock	Sell	Dispose S	No	No	5.55	190	1.05 k	209,548
15 Nov 24	Tuan Tu Diep	Common Stock	Sell	Dispose S	No	No	5.55	85	471.75	101,748
28 Oct 24	Paul A. Grayson	Stock Option Common Stock	Grant	Acquire A	No	No	5.15	70,000	360.50 k	70,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Skye Bioscience Q3 2024 GAAP EPS $(0.10) Beats $(0.23) Estimate

Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 56.52 percent. This is a 96.85 percent increase over losses of $(3.17) per share from

Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space.

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Micro-cap stocks are typically categorized as companies with market capitalizations between $50 million and $300 million. However, it's not a hard-and-fast rule. Many small stocks can fluctuate massively in price over a short time. This can put their value inside or outside that range on a given day.

Scotiabank Initiates Coverage On Skye Bioscience with Sector Outperform Rating, Announces Price Target of $20

Press releases

From Benzinga Pro

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health,

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data shows that nimacimab

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.